Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19)

Peer Review reports

Original Submission
8 Dec 2020	Submitted	Original manuscript
9 Dec 2020	Reviewed	Reviewer Report - Kirsty Loudon
Resubmission - Version 2
	Submitted	Manuscript version 2
Publishing
14 Dec 2020	Editorially accepted
4 Jan 2021	Article published	10.1186/s13063-020-04976-x

Back to article page